Clinical Trials Update: Oct. 18, 2006
Sleep Disorders Asthma Rheumatoid Arthritis
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This research study will evaluate how weight loss and treatment for sleep apnea affect a person's risks of heart disease and diabetes. Volunteers 18 to 80 with symptoms of obstructive sleep apnea and who are overweight (BMI equal to or greater than 30) may be eligible. Patients with diabetes, history of heart attack or stroke, chronic high blood pressure, or a previous hospitalization for breathing problems will not be included.
The research site is in Philadelphia, Penn.
This study will evaluate the effectiveness and safety of pleconaril nasal spray (SCH 900819) compared to a placebo (an inactive nasal spray) in preventing worsening asthma symptoms and common cold symptoms after exposure to someone else with a cold. SCH 900819 is an experimental antiviral compound that has not been approved by the U.S. Food and Drug Administration.
The research site is in Spartanburg, SC.
This clinical trial will determine the effectiveness and safety of an investigational medication in people with active rheumatoid arthritis (RA) who have an inadequate clinical response to methotrexate therapy. Candidates 18 older who are being treated for RA and have received methotrexate for at least 24 weeks may qualify.
The research site is in Gainesville, Fla.
Copyright 2006 Thomson CenterWatch. All rights reserved.